Fiera Capital Corp Raises Stock Position in Insmed, Inc. $INSM

Fiera Capital Corp boosted its position in shares of Insmed, Inc. (NASDAQ:INSM) by 22.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 992,892 shares of the biopharmaceutical company’s stock after buying an additional 183,771 shares during the quarter. Fiera Capital Corp’s holdings in Insmed were worth $172,803,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. CIBC Private Wealth Group LLC raised its stake in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the period. CoreCap Advisors LLC purchased a new stake in shares of Insmed in the 4th quarter valued at approximately $27,000. SBI Securities Co. Ltd. raised its stake in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares during the period. GraniteShares Advisors LLC purchased a new stake in shares of Insmed in the 4th quarter valued at approximately $30,000. Finally, RiverPark Advisors LLC purchased a new stake in shares of Insmed in the 3rd quarter valued at approximately $38,000.

Insmed Stock Performance

Shares of INSM stock opened at $94.22 on Monday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. The stock has a market capitalization of $20.42 billion, a P/E ratio of -16.39 and a beta of 0.79. The company has a 50 day moving average price of $130.45 and a 200 day moving average price of $154.65. Insmed, Inc. has a fifty-two week low of $70.57 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The business’s quarterly revenue was up 229.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.42) earnings per share. Equities research analysts predict that Insmed, Inc. will post -2.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on INSM. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Guggenheim reduced their price target on shares of Insmed from $230.00 to $226.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Mizuho boosted their price target on shares of Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. Morgan Stanley raised shares of Insmed from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $166.00 to $212.00 in a research note on Monday, March 30th. Finally, HC Wainwright reissued a “buy” rating on shares of Insmed in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and an average price target of $210.50.

Insider Buying and Selling at Insmed

In related news, insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $150.98, for a total value of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares in the company, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 2,404 shares of Insmed stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $245,857.08. Following the completion of the transaction, the chief financial officer owned 69,082 shares of the company’s stock, valued at $7,065,016.14. This trade represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 160,482 shares of company stock worth $24,438,193. 2.10% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.